Literature DB >> 28145427

Variability in assigning pathogenicity to incidental findings: insights from LDLR sequence linked to the electronic health record in 1013 individuals.

Maya S Safarova1, Eric W Klee2, Linnea M Baudhuin3, Erin M Winkler4, Michelle L Kluge3, Suzette J Bielinski2, Janet E Olson2, Iftikhar J Kullo1.   

Abstract

Knowledge of variant pathogenicity is key to implementing genomic medicine. We describe variability between expert reviewers in assigning pathogenicity to sequence variants in LDLR, the causal gene in the majority of cases of familial hypercholesterolemia. LDLR was sequenced on the Illumina HiSeq platform (average read depth >200 × ) in 1013 Mayo Biobank participants recruited from 2012 to 2013. Variants with a minor allele frequency (MAF) <5% predicted to be functional or referenced in HGMD (Human Gene Mutation Database) or NCBI-ClinVar databases were reviewed. To assign pathogenicity, variant frequency in population data sets, computational predictions, reported observations and patient-level data including electronic health record-based post hoc phenotyping were leveraged. Of 178 LDLR variants passing quality control, 25 were selected for independent review using either an in-house protocol or a disease/gene-specific semi-quantitative framework based on the American College of Medical Genetics and Genomics-recommended lines of evidence. NCBI-ClinVar included interpretations for all queried variants with 74% (14/19) of variants with >1 submitter showing inconsistency in classification and 26% (5/19) appearing with conflicting clinical actionability. The discordance rate (one-step level of disagreement out of five classes in variant interpretation) between the reviewers was 40% (10/25). Two LDLR variants were independently deemed clinically actionable and returnable. Interpretation of LDLR variants was often discordant among ClinVar submitters and between expert reviewers. A quantitative approach based on strength of each predefined criterion in the context of specific genes and phenotypes may yield greater consistency between different reviewers.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28145427      PMCID: PMC5386413          DOI: 10.1038/ejhg.2016.193

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  28 in total

1.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

Authors:  Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo
Journal:  Genome Res       Date:  2010-07-19       Impact factor: 9.043

Review 2.  The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association.

Authors:  Samuel S Gidding; Mary Ann Champagne; Sarah D de Ferranti; Joep Defesche; Matthew K Ito; Joshua W Knowles; Brian McCrindle; Frederick Raal; Daniel Rader; Raul D Santos; Maria Lopes-Virella; Gerald F Watts; Anthony S Wierzbicki
Journal:  Circulation       Date:  2015-10-28       Impact factor: 29.690

3.  Actionable, pathogenic incidental findings in 1,000 participants' exomes.

Authors:  Michael O Dorschner; Laura M Amendola; Emily H Turner; Peggy D Robertson; Brian H Shirts; Carlos J Gallego; Robin L Bennett; Kelly L Jones; Mari J Tokita; James T Bennett; Jerry H Kim; Elisabeth A Rosenthal; Daniel S Kim; Holly K Tabor; Michael J Bamshad; Arno G Motulsky; C Ronald Scott; Colin C Pritchard; Tom Walsh; Wylie Burke; Wendy H Raskind; Peter Byers; Fuki M Hisama; Deborah A Nickerson; Gail P Jarvik
Journal:  Am J Hum Genet       Date:  2013-09-19       Impact factor: 11.025

4.  Genetic Misdiagnoses and the Potential for Health Disparities.

Authors:  Arjun K Manrai; Birgit H Funke; Heidi L Rehm; Morten S Olesen; Bradley A Maron; Peter Szolovits; David M Margulies; Joseph Loscalzo; Isaac S Kohane
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245

5.  Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.

Authors:  K Haralambos; S D Whatley; R Edwards; R Gingell; D Townsend; P Ashfield-Watt; P Lansberg; D B N Datta; I F W McDowell
Journal:  Atherosclerosis       Date:  2015-03-06       Impact factor: 5.162

6.  Actionable exomic incidental findings in 6503 participants: challenges of variant classification.

Authors:  Laura M Amendola; Michael O Dorschner; Peggy D Robertson; Joseph S Salama; Ragan Hart; Brian H Shirts; Mitzi L Murray; Mari J Tokita; Carlos J Gallego; Daniel Seung Kim; James T Bennett; David R Crosslin; Jane Ranchalis; Kelly L Jones; Elisabeth A Rosenthal; Ella R Jarvik; Andy Itsara; Emily H Turner; Daniel S Herman; Jennifer Schleit; Amber Burt; Seema M Jamal; Jenica L Abrudan; Andrew D Johnson; Laura K Conlin; Matthew C Dulik; Avni Santani; Danielle R Metterville; Melissa Kelly; Ann Katherine M Foreman; Kristy Lee; Kent D Taylor; Xiuqing Guo; Kristy Crooks; Lesli A Kiedrowski; Leslie J Raffel; Ora Gordon; Kalotina Machini; Robert J Desnick; Leslie G Biesecker; Steven A Lubitz; Surabhi Mulchandani; Greg M Cooper; Steven Joffe; C Sue Richards; Yaoping Yang; Jerome I Rotter; Stephen S Rich; Christopher J O'Donnell; Jonathan S Berg; Nancy B Spinner; James P Evans; Stephanie M Fullerton; Kathleen A Leppig; Robin L Bennett; Thomas Bird; Virginia P Sybert; William M Grady; Holly K Tabor; Jerry H Kim; Michael J Bamshad; Benjamin Wilfond; Arno G Motulsky; C Ronald Scott; Colin C Pritchard; Tom D Walsh; Wylie Burke; Wendy H Raskind; Peter Byers; Fuki M Hisama; Heidi Rehm; Debbie A Nickerson; Gail P Jarvik
Journal:  Genome Res       Date:  2015-01-30       Impact factor: 9.043

7.  Assessment of incidental findings in 232 whole-exome sequences from the Baylor-Hopkins Center for Mendelian Genomics.

Authors:  Julie Jurgens; Hua Ling; Kurt Hetrick; Elizabeth Pugh; Francois Schiettecatte; Kimberly Doheny; Ada Hamosh; Dimitri Avramopoulos; David Valle; Nara Sobreira
Journal:  Genet Med       Date:  2015-01-08       Impact factor: 8.822

8.  Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations.

Authors:  Marta Futema; Vincent Plagnol; KaWah Li; Ros A Whittall; H Andrew W Neil; Mary Seed; Stefano Bertolini; Sebastiano Calandra; Olivier S Descamps; Colin A Graham; Robert A Hegele; Fredrik Karpe; Ronen Durst; Eran Leitersdorf; Nicholas Lench; Devaki R Nair; Handrean Soran; Frank M Van Bockxmeer; Steve E Humphries
Journal:  J Med Genet       Date:  2014-07-01       Impact factor: 6.318

9.  Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems.

Authors:  L J Rasmussen-Torvik; S C Stallings; A S Gordon; B Almoguera; M A Basford; S J Bielinski; A Brautbar; M H Brilliant; D S Carrell; J J Connolly; D R Crosslin; K F Doheny; C J Gallego; O Gottesman; D S Kim; K A Leppig; R Li; S Lin; S Manzi; A R Mejia; J A Pacheco; V Pan; J Pathak; C L Perry; J F Peterson; C A Prows; J Ralston; L V Rasmussen; M D Ritchie; S Sadhasivam; S A Scott; M Smith; A Vega; A A Vinks; S Volpi; W A Wolf; E Bottinger; R L Chisholm; C G Chute; J L Haines; J B Harley; B Keating; I A Holm; I J Kullo; G P Jarvik; E B Larson; T Manolio; C A McCarty; D A Nickerson; S E Scherer; M S Williams; D M Roden; J C Denny
Journal:  Clin Pharmacol Ther       Date:  2014-06-24       Impact factor: 6.875

10.  A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation.

Authors:  Jessica Ezzell Hunter; Stephanie A Irving; Leslie G Biesecker; Adam Buchanan; Brian Jensen; Kristy Lee; Christa Lese Martin; Laura Milko; Kristin Muessig; Annie D Niehaus; Julianne O'Daniel; Margaret A Piper; Erin M Ramos; Sheri D Schully; Alan F Scott; Anne Slavotinek; Nara Sobreira; Natasha Strande; Meredith Weaver; Elizabeth M Webber; Marc S Williams; Jonathan S Berg; James P Evans; Katrina A B Goddard
Journal:  Genet Med       Date:  2016-04-28       Impact factor: 8.822

View more
  7 in total

1.  Analyzing and Reanalyzing the Genome: Findings from the MedSeq Project.

Authors:  Kalotina Machini; Ozge Ceyhan-Birsoy; Danielle R Azzariti; Himanshu Sharma; Peter Rossetti; Lisa Mahanta; Laura Hutchinson; Heather McLaughlin; Robert C Green; Matthew Lebo; Heidi L Rehm
Journal:  Am J Hum Genet       Date:  2019-06-27       Impact factor: 11.025

2.  Challenges in returning results in a genomic medicine implementation study: the Return of Actionable Variants Empirical (RAVE) study.

Authors:  David C Kochan; Erin Winkler; Noralane Lindor; Gabriel Q Shaibi; Janet Olson; Pedro J Caraballo; Robert Freimuth; Joel E Pacyna; Carmen Radecki Breitkopf; Richard R Sharp; Iftikhar J Kullo
Journal:  NPJ Genom Med       Date:  2020-05-04       Impact factor: 8.617

Review 3.  Genomic medicine for kidney disease.

Authors:  Emily E Groopman; Hila Milo Rasouly; Ali G Gharavi
Journal:  Nat Rev Nephrol       Date:  2018-01-08       Impact factor: 28.314

Review 4.  Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care.

Authors:  Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray
Journal:  Nat Rev Cardiol       Date:  2020-01-23       Impact factor: 32.419

5.  Interpretation of Incidental Genetic Findings Localizing to Genes Associated With Cardiac Channelopathies and Cardiomyopathies.

Authors:  Jordan E Ezekian; Catherine Rehder; Priya S Kishnani; Andrew P Landstrom
Journal:  Circ Genom Precis Med       Date:  2021-08-13

6.  Evaluation of a novel rapid genomic test including polygenic risk scores for the diagnosis and management of familial hypercholesterolaemia.

Authors:  Emma Neves; Tina Khan; Maggie Williams; Marta Carrera; Winston Banya; Ramon Brugada; Carles Ferrer; Deborah J Morris-Rosendahl; Mahmoud Barbir
Journal:  Glob Cardiol Sci Pract       Date:  2021-12-31

7.  Challenges in returning results in a genomic medicine implementation study: the Return of Actionable Variants Empirical (RAVE) study.

Authors:  David C Kochan; Erin Winkler; Noralane Lindor; Gabriel Q Shaibi; Janet Olson; Pedro J Caraballo; Robert Freimuth; Joel E Pacyna; Carmen Radecki Breitkopf; Richard R Sharp; Iftikhar J Kullo
Journal:  NPJ Genom Med       Date:  2020-05-04       Impact factor: 8.617

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.